|
|
|
|
Дата |
|---|
| 22.09.2026 |
| 21.09.2026 |
| 18.09.2026 |
| 17.09.2026 |
| 16.09.2026 |
| 15.09.2026 |
| 14.09.2026 |
| 11.09.2026 |
| 10.09.2026 |
| 09.09.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
24.78
|
30.93
|
29.565
|
29.565
|
30.28
|
30.19
|
|
|
13 615 190.28
|
7 376.00
|
|
24.78
|
29.93
|
28.67
|
28.60
|
29.73
|
29.59
|
|
|
6 131 298.20
|
4 900.00
|
|
24.78
|
29.93
|
28.77
|
28.51
|
29.11
|
28.55
|
|
|
13 191 123.47
|
6 242.00
|
|
24.78
|
29.93
|
27.92
|
27.92
|
28.97
|
28.91
|
|
|
13 351 732.64
|
7 394.00
|
|
24.78
|
29.93
|
27.93
|
27.24
|
27.995
|
27.53
|
|
|
11 509 235.28
|
6 131.00
|
|
25.00
|
29.93
|
26.71
|
26.63
|
28.07
|
27.92
|
|
|
24 235 234.51
|
7 374.00
|
|
25.00
|
29.93
|
27.02
|
26.66
|
27.075
|
26.71
|
|
|
6 697 294.63
|
4 766.00
|
|
24.78
|
29.93
|
27.30
|
26.78
|
27.30
|
26.81
|
|
|
6 619 040.64
|
4 842.00
|
|
24.78
|
29.93
|
27.29
|
26.80
|
27.30
|
26.81
|
|
|
4 582 752.34
|
4 237.00
|
|
27.39
|
29.93
|
27.59
|
27.40
|
27.93
|
27.43
|
|
|
3 607 799.14
|
3 739.00
|
Lakefront Biotherapeutics NV is a Belgiumbased company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses dealmaking capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinicalstage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than inhouse cell therapy platforms. It builds a portfolio of clinicalstage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.
Американская биофармацевтическая компания Gilead Sciences купит права на использование результатов исследований и разработок у Galapagos NV, сообщается в пресс –релизе Gilead. Десятилетний контракт обойдется Gilead в $5,1 млрд. Сделка не...
| 07.05.2026 |
|
| 24.02.2026 |
|
| 06.11.2025 |
|
| 24.04.2025 |
|
| 13.02.2025 |
|